Ardelyx Seeks Profitability by 2027 Amid Payer Challenges

Ardelyx Inc. (ARDX) presented at the Cantor Fitzgerald Global Healthcare Conference on September 10, 2026, outlining its trajectory toward profitability by 2027 while navigating payer resistance and competitive dynamics in its specialty pharmaceuticals portfolio. The company’s lead product, IBSRELA, generated $274 million in 2024—a 73% year-over-year increase—and is projected to reach $350 million to $370 million in 2025, reflecting a midpoint growth rate of roughly 50%. Long-term sales targets remain at $1 billion, though the compound annual growth rate needed to achieve this has narrowed to 31% from the prior 38% estimate. IBSRELA’s gross-to-net discount stands at 34%, leaving Ardelyx with about 66% of gross revenue, while its 98% gross profit margins underscore its cost-efficient manufacturing of the 299 formulation, which extends patent protection through 2042, with potential additional exclusivity from pediatric trials. The company has not yet faced Paragraph IV challenges from generics, though it anticipates a 24-month timeline for any potential ANDA filings if they occur.